HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA: “Extreme” Anti-Aging Claims Led To 2012 Warning Letters

This article was originally published in The Rose Sheet

Executive Summary

A proliferation of “extreme” anti-aging cosmetic claims that crossed the line into drug territory led to FDA’s cluster of warning letters in 2012, according to Jennifer Thomas, director of the division of enforcement in the Center for Food Safety and Applied Nutrition’s office of compliance,

You may also be interested in...



Marketplace As Enforcer? FDA Cedes Onus To Litigants – Attorney

Pointing to the uptick in consumer class actions targeting cosmetics claims and the lull in FDA enforcement action in the sector since the 2012 warning-letter blitz, Arent Fox partner Georgia Ravitz speculates that the agency is “letting the marketplace now scrutinize product label claims to determine whether they’re false or misleading.”

FDA Guidance Could Impose Drug-Like Burden On Cosmetic Trials

An FDA guidance document intended to clarify if firms conducting certain drug studies involving human subjects are obligated to file Investigational New Drug Applications instead raises questions for the cosmetics industry.

Living Proof, Valeant Pharma To Market Strateris Skin Lifter To Doctors

An initial product featuring Living Proof’s Strateris polymer film technology, designed to combat gravity’s effect on aging skin, is slated to launch in March under a joint venture with Valeant Pharmaceuticals. The move will extend Living Proof’s portfolio beyond hair care and provide access to the physician channel.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS018799

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel